Giraldez, Maria D http://orcid.org/0000-0001-6829-7603
Spengler, Ryan M http://orcid.org/0000-0003-0181-5589
Etheridge, Alton
Godoy, Paula M
Barczak, Andrea J
Srinivasan, Srimeenakshi
De Hoff, Peter L
Tanriverdi, Kahraman
Courtright, Amanda
Lu, Shulin
Khoory, Joseph
Rubio, Renee
Baxter, David
Driedonks, Tom A P
Buermans, Henk P J
Nolte-'t Hoen, Esther N M http://orcid.org/0000-0002-3172-9959
Jiang, Hui http://orcid.org/0000-0003-2718-9811
Wang, Kai
Ghiran, Ionita
Wang, Yaoyu E
Van Keuren-Jensen, Kendall
Freedman, Jane E
Woodruff, Prescott G
Laurent, Louise C
Erle, David J http://orcid.org/0000-0002-2171-0648
Galas, David J
Tewari, Muneesh
Article History
Received: 24 February 2017
Accepted: 1 May 2018
First Online: 16 July 2018
Change Date: 31 July 2018
Change Type: Erratum
Change Date: 1 October 2018
Change Type: Erratum
Change Details: In the version of this article initially published online, the text "Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute (BIDMC/ DFCI)" was inserted into the last sentence in the right-hand column of p.10, beginning "It is worth noting...." . In addition, on p.2, the acronym for The Cancer Genome Atlas was given as TGCA, rather than TCGA; and on p. 3, UUTR should have been defined, as University of Utrecht, the Netherlands. Finally, ref. 48 was cited in the Online Methods after "4N_Xu protocol was performed as previously described35"; this extra citation has been deleted. The errors have been corrected for the print, PDF and HTML versions of this article.
Change Details: Nat. Biotechnol. 10.1038/nbt.4183; corrected online 31 July 2018 In the version of this article initially published online, the text “Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute (BIDMC/DFCI)” was inserted into the last sentence in the right-hand column of p.10, beginning “It isworth noting.
Competing interests
: The spouse of L.C. Laurent is an employee of Illumina, Inc., the manufacturer of the TruSeq Small RNA Library Preparation Kit. L.C. Laurent and her spouse's equity interest in Illumina, Inc. represents <<1% of the company. The other authors declare no competing financial interests.